SDPC Stock Overview
Engages in the distribution and trading of prescription and non-prescription medicines and medical devices in Indonesia. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 1/6 |
| Financial Health | 2/6 |
| Dividends | 2/6 |
PT Millennium Pharmacon International Tbk Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | Rp166.00 |
| 52 Week High | Rp183.00 |
| 52 Week Low | Rp121.00 |
| Beta | 0.54 |
| 11 Month Change | 13.70% |
| 3 Month Change | 24.81% |
| 1 Year Change | 0% |
| 33 Year Change | 13.70% |
| 5 Year Change | 71.13% |
| Change since IPO | 848.57% |
Recent News & Updates
Recent updates
Shareholder Returns
| SDPC | ID Healthcare | ID Market | |
|---|---|---|---|
| 7D | 5.1% | -3.1% | -2.2% |
| 1Y | 0% | 19.3% | 9.3% |
Return vs Industry: SDPC underperformed the ID Healthcare industry which returned 19.3% over the past year.
Return vs Market: SDPC underperformed the ID Market which returned 9.3% over the past year.
Price Volatility
| SDPC volatility | |
|---|---|
| SDPC Average Weekly Movement | 7.4% |
| Healthcare Industry Average Movement | 5.8% |
| Market Average Movement | 5.5% |
| 10% most volatile stocks in ID Market | 12.6% |
| 10% least volatile stocks in ID Market | 2.4% |
Stable Share Price: SDPC has not had significant price volatility in the past 3 months compared to the ID market.
Volatility Over Time: SDPC's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1952 | 1,172 | Ahmad Bin Abu Bakar | www.mpi-indonesia.co.id |
PT Millennium Pharmacon International Tbk engages in the distribution and trading of prescription and non-prescription medicines and medical devices in Indonesia. As of December 31, 2022, it operated 33 branch offices in Java, Bali, Sumatera, Kalimantan, and Sulawesi Islands. The company was formerly known as PT NVPD Soedarpo Corporation Tbk and changed its name to PT Millennium Pharmacon International Tbk in February 1990.
PT Millennium Pharmacon International Tbk Fundamentals Summary
| SDPC fundamental statistics | |
|---|---|
| Market cap | Rp211.48b |
| Earnings (TTM) | Rp26.87b |
| Revenue (TTM) | Rp3.85t |
7.9x
P/E Ratio0.1x
P/S RatioIs SDPC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SDPC income statement (TTM) | |
|---|---|
| Revenue | Rp3.85t |
| Cost of Revenue | Rp3.52t |
| Gross Profit | Rp326.25b |
| Other Expenses | Rp299.37b |
| Earnings | Rp26.87b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 21.09 |
| Gross Margin | 8.48% |
| Net Profit Margin | 0.70% |
| Debt/Equity Ratio | 295.5% |
How did SDPC perform over the long term?
See historical performance and comparison